ISG20L2

Across TCGA pan-cancer cohorts, ISG20L2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ISG20L2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ISG20L2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ISG20L2 is over-expressed in tumor.

COAD, CCRCC, and HNSC are the cancer types where ISG20L2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ISG20L2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	III,IV	+0.593	<.001	11	view →
CCRCC	Male	III,IV	+0.546	<.001	11	view →
HNSC	Male	IV	+0.435	<.001	11	view →
LSCC	Male	II,III,IV	+0.782	<.001	9	view →
LUAD	Male	III,IV	+0.617	<.001	8	view →
OV	All	All	+0.463	.025	2	view →
PDAC	Female	III,IV	+0.474	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ISG20L2–COAD

Open the COAD breakdown →